title: Could calcitonin be a useful therapeutic agent for trigeminal neuralgia?
abstract: Trigeminal neuralgia (TN) has been recognized as one of the most common neurovascular syndromes caused by the vascular contact of the trigeminal nerve in its root entry zone (REZ) with a branch of the superior or anterior inferior cerebellar arteries, leading to a demyelinization of trigeminal sensory fibers within either the nerve root or, less commonly, the brainstem. There is a lack of certainty regarding the aetiology and pathophysiology of TN, therefore the treatment of trigeminal neuropathic pain disorders continues to be a major therapeutic challenge. The identification of novel therapeutic agents for the treatment of these disorders is important. Calcitonin (especially intranasal) provides an interesting analgesic effect in a series of painful conditions including reflex sympathetic dystrophy syndrome, adhesive capsulitis, ankylosing spondylitis, rheumatoid arthritis, vertebral crush fractures and metastasis, phantom limb pain, etc. Exogenous calcitonin is thought to cross the blood-brain barrier and to accumulate slowly in the brain, inducing analgesia once sufficient receptors are occupied. We hypothesize that calcitonin may has anti - trigeminal neuralgia properties. From the clinical point of use, the analgesic effect of calcitonin will be beneficial throughout the whole period of medical treatment of trigeminal neuralgia patients.
authors.affiliation: Department of pedo-stomatology, Oral medical hospital, The Fourth Military Medical University, #17 Changle Western Road, Xi'an, China.
authors.forename: Han
authors.initials: H
authors.lastname: Qin
authors.forename: Jun
authors.initials: J
authors.lastname: Cai
authors.forename: Fu Sheng
authors.initials: FS
authors.lastname: Yang
mesh_terms: D000700:Analgesics / Q000493:pharmacokinetics / Q000627:therapeutic use; D000818:Animals; D001812:Blood-Brain Barrier; D002116:Calcitonin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008959:Models, Neurological; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use; D014277:Trigeminal Neuralgia / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism
chemical_list: D000700:Analgesics; D011994:Recombinant Proteins; C028815:salmon calcitonin; D002116:Calcitonin